PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.92%
Revenue growth 1.25-1.5x Medical - Pharmaceuticals median of 0.76%. Mohnish Pabrai would see if this gap is sustainable or cyclical.
3.15%
Gross profit growth 50-75% of Medical - Pharmaceuticals median of 4.85%. Guy Spier might worry about insufficient cost control or weaker pricing.
32.84%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 10.09%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
28.75%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 10.09%. Joel Greenblatt would see if unique processes drive exceptional profitability.
25.93%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 13.15%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
25.93%
EPS growth 1.25-1.5x Medical - Pharmaceuticals median of 17.65%. Mohnish Pabrai would see if the company’s capital allocation strategy boosts these results.
25.93%
Diluted EPS growth 1.25-1.5x Medical - Pharmaceuticals median of 17.65%. Mohnish Pabrai might attribute the gap to effective capital allocation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
142.00%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 30.32%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
46.86%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 20.52%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
31.11%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 8.93%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
182.37%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 47.98% over a decade. Joel Greenblatt might see a standout compounder of earnings.
44.64%
5Y net income/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff would encourage better profitability or share buybacks to catch up with peers.
51.81%
3Y net income/share CAGR near Medical - Pharmaceuticals median. Charlie Munger sees standard sector-level performance in the last few years.
304.14%
Equity/share CAGR of 304.14% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
79.56%
5Y equity/share CAGR of 79.56% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
35.29%
Positive short-term equity/share CAGR while Medical - Pharmaceuticals is negative. Peter Lynch finds a relative advantage vs. sector-level slowdown.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
62.50%
3Y dividend/share CAGR of 62.50% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
-1.61%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-6.17%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-2.56%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
2.19%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
11.12%
Slightly rising debt while Medical - Pharmaceuticals median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
No Data
No Data available this quarter, please select a different quarter.
-1.84%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.